We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Favoured treatment

9 Nov 2021 By Aimee Donnellan

The $106 bln drugmaker’s plan to spin off its Advil unit has drawn interest from industry giants and private equity firms. A leveraged buyout would stretch even the most daring financial buyers and leave GSK with a chunky stake. Selling to a rival like P&G looks a cleaner option.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)